The FDA has recently approved exciting new treatments that can slow the progression of Alzheimer’s disease, a scourge that claims more American lives than breast cancer and prostate cancer combined.

A potential new Alzheimer’s drug represses the harmful inflammatory response of the brain’s immune cells, reducing disease ...

The vote essentially upheld the Food and Drug Administration’s earlier rulings, with some members calling for new clinical ...

USC researchers played a key role in a new treatment for Alzheimer’s disease, the first with full approval to target a suspected root cause of the condition, offering hope to those with the disease ...

An advisory committee to the U.S. Food and Drug Administration unanimously rejected a drug-and-device combination made by a Boston biotech, which the agency had already rejected twice.

For decades, attempts to treat or slow Alzheimer's disease (AD) — a brain disorder that causes dementia through damage to brain cells and other changes in the brain — have been dispiriting ...

Use one of the services below to sign in to PBS: You've just tried to add this video to My List. But first, we need you to sign in to PBS using one of the services below. You've just tried to add ...

The 19-member advisory committee unanimously voted against Intarcia in the review, citing cardiovascular and kidney safety concerns.

For anyone who has or knows someone who has Alzheimer’s disease, a progressive and irreversible form of dementia that’s ultimately deadly, it can sometimes be difficult to find hope.

Arialys Therapeutics launched Tuesday with $58 million in funding from a group of life sciences investors that includes Johnson & Johnson’s venture arm.

The U.S. approved updated COVID-19 vaccines Monday, hoping to rev up protection against the latest coronavirus strains and ...

A CMS pilot project will test a low-cost way to help families support a suffering loved one. It’s more promising than ...